Takeda submits marketing authorisation application for gut-selective humanised monoclonal antibody.
M2 EQUITYBITES-March 8, 2013-Takeda submits marketing authorisation application for gut-selective humanised monoclonal antibody(C)2013 M2 COMMUNICATIONS http://www.m2.com
Takeda Pharmaceutical Company, a research-based global pharmaceutical company, has submitted a marketing authorisation application requiring approval from the European Medicines Agency for its investigational, gut-selective humanised monoclonal antibody.
It is reported today that the antibody is to be used for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
Vedolizuma, a monoclonal antibody, provokes alpha4beta7 integrin expressed on a subset of circulating white blood cells, and treats most common types of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 8, 2013|
|Previous Article:||Cerberus looks to up Seibu interest to 33.4% - report.|
|Next Article:||RetroSense receives notice of allowance for patent application No. 12/299,574.|